EP 119 | Q3 Earnings from $JNJ $ASML $CAST & many more!
Dividend Talk
00:00
I'm a Big Fan of Johnson and I Think It's a Good Thing They're Doing a Lot Better in Europe Than the US
The company has restructured rebranded they are now not as reliant on their cancer drugs. The new products are really really starting to earn nearly 50 60% of their the revenue which is quite interesting. diagnostics this division is doing really well we know they invest heavily in R&D and pushing boundaries.
Transcript
Play full episode
